Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Sewanti Limaye; Darshana Patil; Dadasaheb Akolkar; Navin Srivastava; Revati Patil; Sachin Apurwa; Sanket Patil; Jinumary John; Rahul Gosavi; Prabhu Nesargikar; Prashant Kumar; Vineet Datta; Chirantan Bose; Zarrine Raazi; Ajay Srinivasan; Rajan Datar

doi:10.1002/ccr3.4986

Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Clin Case Rep. 2021 Nov 7;9(11):e04986. doi: 10.1002/ccr3.4986. eCollection 2021 Nov.

Authors

Sewanti Limaye¹, Darshana Patil², Dadasaheb Akolkar², Navin Srivastava², Revati Patil², Sachin Apurwa², Sanket Patil², Jinumary John², Rahul Gosavi², Prabhu Nesargikar³, Prashant Kumar^{4

5

6}, Vineet Datta², Chirantan Bose², Zarrine Raazi², Ajay Srinivasan², Rajan Datar²

Affiliations

¹ Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai Maharashtra India.
² Datar Cancer Genetics Nasik Maharashtra India.
³ HCG Cancer Centre Bengaluru Karnataka India.
⁴ Institute of Bioinformatics Bengaluru Karnataka India.
⁵ Manipal Academy of Higher Education Manipal Karnataka India.
⁶ Somaiya Institute of Research and Consultancy Somaiya Vidyavihar University Mumbai Maharashtra India.

Abstract

Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti-cancer agents for treatment of Gastric cancers.

Keywords: combination regimen; encyclopedic tumor analysis; gastric adenocarcinoma; pazopanib; personalized cancer treatment; precision oncology; stomach cancer.

Publication types

Case Reports